In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Autolus Therapeutics Plc (NASDAQ: AUTL), with a price target of $45. The company’s shares opened today at $32, close to its 52-week high of $34.22.
Chattopadhyay observed:
“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.45, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 37.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Autolus Therapeutics Plc with a $45 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.22 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 45.82K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc operates as a holding company, which engages in the development of cancer treatments. Its portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.